KF24345, an Adenosine Uptake Inhibitor, Suppresses Lipopolysaccharide-Induced Tumor Necrosis Factor-α Production and Leukopenia via Endogenous Adenosine in Mice

  1. Tohru Noji,
  2. Makoto Takayama,
  3. Mirai Mizutani,
  4. Yuko Okamura,
  5. Haruki Takai,
  6. Akira Karasawa and
  7. Hideaki Kusaka
  1. Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan
  1. Tohru Noji, Licensing and Business Development, Kyowa Hakko Kogyo Co., Ltd., 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo 100-8185, Japan. E-mail:tohru.noji{at}kyowa.co.jp
 
Next Section

Abstract

3-[1-(6,7-Diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6-dimethyl-2,4(1H,3H)-quinazolinedione hydrochloride (KF24345) is a novel potent adenosine uptake inhibitor. KF24345 inhibited [3H]adenosine uptake into erythrocytes from human, mouse, rabbit, and hamster with IC50 values of 59.5, 130.1, 104.2, and 30.9 nM, respectively. In mice, oral administration of KF24345 at 10 mg/kg almost completely inhibited the [3H]adenosine uptake into sampled blood cells at least up to 10 h of the administration. In this study, to examine whether the adenosine uptake inhibition exhibits anti-inflammatory effects, we determined the effects of KF24345 on lipopolysaccharide (LPS)-induced tumor necrosis factor-α (TNF-α) production and leukopenia in mice. KF24345 (10 mg/kg p.o.) significantly suppressed the elevation of serum TNF-α concentration after the LPS injection, and the suppressing effect of KF24345 was abolished by the treatment with 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol, a selective adenosine A2 receptor antagonist, but not with 8-(noradamantan-3-yl)-1,3-dipropylxanthine, a selective adenosine A1 receptor antagonist. KF24345 (10 mg/kg p.o.) also inhibited the decrease of leukocytes after the LPS injection, and 8-(p-sulfophenyl)theophylline, a nonselective adenosine receptor antagonist, completely reversed the inhibitory effect of KF24345. These results demonstrate that KF24345 inhibits LPS-induced TNF-α production and leukopenia via enhancing the effect of endogenous adenosine. It is thus suggested that the adenosine uptake inhibitor has anti-inflammatory effects in vivo and represents a novel therapeutic approach to the treatment of various inflammatory diseases.

Adenosine, an endogenous purine nucleoside, has been proposed to modulate a variety of physiological responses by stimulating specific extracellular receptors (Collis and Hourani, 1993). Adenosine receptors have been classified as A1, A2A, A2B, and A3 receptors (Fredholm et al., 1994; Olah and Stiles, 1995). Under several adverse conditions, such as stress, trauma, ischemia, seizures, and pain, the local tissue concentrations of extracellular adenosine are increased after the release of adenosine itself, and/or that of AMP, which is metabolized extracellularly to adenosine. This increased adenosine can protect against excessive cellular damage or dysfunction in negative feedback manners (Ralevic and Burnstock, 1998). Indeed, exogenous adenosine and its agonists attenuate ischemic cerebral injuries (von Lubitz et al., 1988), seizures (Dunwiddie and Worth, 1982; Murray et al., 1985), and pain (Sawynok et al., 1986) in several animal models.

Adenosine is also released at inflamed sites (Cronstein, 1995;Cronstein et al., 1995) and exhibits anti-inflammatory effects (Cronstein, 1997; Rosengren and Firestein, 1997). Although adenosine and its agonists are effective in animal models of inflammation, their therapeutic application has been limited by systemic side effects, such as hypotension, bradycardia, and sedation (Williams, 1996). Moreover, adenosine usually disappears very rapidly in physiological conditions due to rapid uptake into the adjacent cells (erythrocytes, endothelial cells) and subsequent intracellular metabolism (Arch and Newsholme, 1978; Moser et al., 1989). Endogenous adenosine levels at inflamed sites are reported to increase further because of the increased need for energy supplied by ATP, which is metabolized to AMP and adenosine ultimately (Eigler et al., 1997). In addition, the activity of 5′-nucleotidase, which metabolizes AMP to adenosine, is reported to increase in inflammatory conditions (Johnson et al., 1999). It is therefore assumed that prevention of adenosine uptake into the cells and its subsequent metabolism can selectively enhance extracellular concentrations of adenosine at inflamed sites, resulting in an anti-inflammatory effect. In fact, adenosine kinase inhibitors have been shown to exhibit anti-inflammatory effects in vivo (Firestein et al., 1994; Cronstein et al., 1995; Kowaluk et al., 2000). However, there has been no report on anti-inflammatory effects of adenosine uptake inhibitors in vivo.

3-[1-(6,7-Diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6-dimethyl-2,4(1H,3H)-quinazolinedione hydrochloride (KF24345) is a novel adenosine uptake inhibitor with a new chemical structure (Fig. 1). In the present study, we investigated the effects of KF24345 on lipopolysaccharide (LPS)-induced tumor necrosis factor-α (TNF-α) production and leukopenia in mice to determine whether the adenosine uptake inhibitor exerts anti-inflammatory effects in vivo. Moreover, we investigated the effects of adenosine receptor antagonists on the anti-inflammatory effects of KF24345 to determine the involvement of endogenous adenosine and adenosine receptors.

Figure 1
View larger version:
Figure 1

Chemical structure of KF24345.

Previous SectionNext Section

Materials and Methods

Animals.

Male ddY mice (weighing 20–30 g), New Zealand White rabbits (weighing 2–3 kg), and golden Syrian hamsters (weighing 100–200 g) were purchased from Japan SLC Inc. (Hamamatsu, Japan). The animals were given access to food and water ad libitum and were maintained on 12-h light/dark cycle at 22–23°C. All experimental procedures were conformed to the Animal Care and Use Committee protocols filed at Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Japan).

Chemicals.

The sources of materials used in this study were as follows: dilazep (N,N′-bis[3-(3,4,5-trimethoxybenzoyloxy)-propyl]homopiperazine), dipyridamole, and adenosine from Sigma Chemical (St. Louis, MO); [2,8-3H]adenosine (41 Ci/mmol) from PerkinElmer Life Sciences (Boston, MA); LPS (Escherichia coli055:B5) from Difco (Detroit, MI); ZM 241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo [2,3-a] [1,3,5]triazin-5-ylamino]ethyl)phenol) from Tocris Cookson (Bristol, UK); and 8-(p-sulfophenyl)theophylline (8-STP) from Sigma/RBI (Natick, MA). KF24345, 2-(aminocarbonyl)-N-(4-amino-2,6- dichlorophenyl)-4-[5,5-bis(4-fluorophenyl)pentyl]-1-piperazineacetamide (R75231; Beukers et al., 1994) and 8-(noradamantan-3-yl)-1,3-dipropylxanthine (KW-3902; Shimada et al., 1992; Mizumoto et al., 1993) were synthesized at Pharmaceutical Research Institute of Kyowa Hakko Kogyo. All other chemicals and solvents were used in their analytical pure form.

For in vitro studies, adenosine uptake inhibitors (KF24345, dilazep, dipyridamole, and R75231) were dissolved in dimethyl sulfoxide at room temperature. For oral administration, adenosine uptake inhibitors were suspended in 0.5% (w/v) methyl cellulose and given to mice at a volume of 10 ml/kg. LPS and 8-SPT were dissolved in saline. KW-3902 and ZM 241385 were dissolved in saline containing 0.1% (v/v)N,N-dimethylacetamide and 1 mM sodium hydroxide.

Inhibition of Adenosine Uptake (in Vitro).

Blood samples from male healthy volunteers were collected into tubes with 1/10 volume of 3.8% (w/v) sodium citrate. Blood samples from the animals were similarly collected from the abdominal vein under ether anesthesia. After the centrifugation (1000g, 10 min), erythrocytes were washed three times with a 2-fold volume of saline to remove the buffy coats. Washed erythrocytes were resuspended in a transport medium (bicarbonate-free Eagle's basal medium buffered with 10 mM HEPES, pH 7.4). Number of erythrocytes in the suspension was determined by a cell counter (Celltacα MEK-6158; Nihon Kohden Corporation, Tokyo, Japan), and erythrocyte density was adjusted to 2.5 × 109 cells/ml.

Adenosine uptake assays were performed according to the previous method (Baer et al., 1990). Washed erythrocytes were incubated for 1 h with each inhibitor at varying concentrations. Adenosine uptake was started by mixing 100 μl of 2 μM [2,8-3H]adenosine (100,000–150,000 dpm) with 100 μl of erythrocytes (2.5 × 108 cells). After 10-s reaction time, 200 μl of a stopping solution (the transport medium including 2 mM dilazep) was added. Immediately after addition of the stopping solution, 300 μl of dibutyl phthalate was added, followed by centrifugation for 15 s at 10,000g(4°C), and thus the erythrocytes were pelleted under the oil layer. The medium above the oily dibutyl phthalate layer was removed by suction, followed by a wash with 1 ml of saline. Then the oil layer was also aspirated, so that the erythrocyte pellet was left undisturbed. The pelleted erythrocytes were lysed by mixing with 200 μl of 1% (v/v) Triton X-100, and the entire contents were placed into scintillation vials. After addition of 8 ml of scintillation cocktail and thorough mixing, radioactivity was measured by a liquid scintillation counter (LS6500; Beckman Coulter, Inc., Fullerton, CA).

Specific inhibition of adenosine uptake within each experiment was calculated from the following formula: inhibition % ={(radioactivity in the presence of vehicle − radioactivity in the presence of each inhibitor)/(radioactivity in the presence of vehicle − nonspecific radioactivity)} × 100. Nonspecific radioactivity was determined in the presence of the stopping solution.

Inhibition of Adenosine Uptake (ex Vivo).

In vivo effectiveness of adenosine uptake inhibitors was determined in mice according to the previous method (Baer et al., 1991). Each inhibitor was orally administered to mice at varying doses. Whole blood samples (450 μl) were collected with 50 μl of 3.8% (w/v) sodium citrate from the abdominal vein under ether anesthesia at various time intervals after the drug administration, and rapidly diluted 1.5-fold into the transport medium containing 0.38% (w/v) sodium citrate. Adenosine uptake was started by mixing 100 μl of 2 μM [2,8-3H]adenosine (100,000–150,000 dpm) with 100 μl of diluted whole blood. The following procedure was the same as described in “Inhibition of Adenosine Uptake (in Vitro)”.

Effects of KF24345 on LPS-Induced TNF-α Production in Mice.

Mice were orally pretreated with KF24345 (10 mg/kg) or vehicle 1 h before an intravenous injection of LPS (1 mg/kg). Mice were anesthetized with ether and blood samples were collected from the abdominal vein 1 h after the LPS injection. KW-3902 (a selective adenosine A1 receptor antagonist; 0.3 mg/kg) or ZM 241385 (a selective adenosine A2 receptor antagonist; 3 mg/kg) was intravenously injected via the tail vein 10 min before the LPS injection. The intravenous injection of KW-3902 at a dose of 0.1 mg/kg prominently antagonizes 5′-N-ethylcarboxamidoadenosine-induced bradycardia without affecting hypotension in rats (unpublished observation). The intravenous injection of ZM 241385 at 1 mg/kg attenuates adenosine-induced hypotension by over 70% (Poucher et al., 1996), whereas its intravenous injection even at 10 mg/kg did not inhibit the hypotensive and bradycardiac effects of the A3/A1 receptor agonistN6-2-(4-amino-3-iodophenyl)ethyladenosine (Keddie et al., 1996). From these observations, we selected the doses of adenosine antagonists used in the present study so that they selectively antagonize each of adenosine receptors. Blood samples were centrifuged (1200g, 10 min, 4°C), and sera were obtained. Serum TNF-α concentrations were measured by using the enzyme-linked immunosorbent assay kit from Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK) with a sensitivity of 10 pg/ml, and calculated from a standard curve generated with recombinant mouse TNF-α (Amersham Biosciences UK, Ltd.).

Effects of KF24345 on LPS-Induced Leukopenia in Mice.

Mice were orally administered with KF24345 (10 mg/kg) or vehicle 1 h before an intravenous injection of LPS (3 μg/kg). Mice were anesthetized with ether and blood samples anticoagulated with 2 mM EDTA were obtained from the abdominal vein 2 h after the LPS injection. 8-SPT (a nonselective adenosine receptor antagonist; 20 mg/kg) was intravenously injected via the tail vein 10 min before the LPS injection. The dose of 8-SPT used in this study is enough to inhibit the myocardial protective effect of adenosine (Toombs et al., 1992). Number of leukocytes was measured using the cell counter (Celltacα MEK-6158; Nihon Kohden Corporation).

Statistical Analysis.

Data are presented as means ± S.E. Statistical significance was calculated by the Student'st test when comparing two groups, or by one-way analysis of variance followed by the Dunnett's test for multiple groups.P < 0.05 was considered to be statistically significant.

Previous SectionNext Section

Results

Inhibition of Adenosine Uptake (in Vitro).

We determined the in vitro potencies of KF24345 as an adenosine uptake inhibitor in erythrocytes isolated from different species, and compared them with those of other adenosine uptake inhibitors.

Figure 2 shows representative curves for adenosine uptake inhibition in human and mouse erythrocytes. Like other inhibitors, KF24345 inhibited adenosine uptake in a concentration-dependent manner, and essentially full inhibition of adenosine uptake was achieved by its submicromolar concentrations in all species tested in this study. There was no indication of the existence of any biphasic inhibition curves, although the possibility of high- and low-affinity binding sites for uptake inhibitors was suggested previously in rat erythrocytes (Jarvis and Young, 1986).

Figure 2
View larger version:
Figure 2

Representative inhibition curves with various adenosine uptake inhibitors in isolated erythrocytes from human (A) and mouse (B). Erythrocytes were incubated with 1 μM [3H]adenosine for 10 s in the presence of various concentrations of adenosine uptake inhibitors. Values are means ± S.E. of five separate experiments. IC50 values are given in Table 1. ●, KF24345; ▪, dilazep; ■, dipyridamole; ○,R75231.

Table 1 summarizes the IC50 values for the uptake inhibitors in different species studied here. Among all the agents tested, dilazep was the most potent in all the species. When compared with other inhibitors, KF24345 was slightly less potent than dilazep but substantially as potent as R75231. The inhibitory activities of KF24345 were not remarkably different among all the species tested.

View this table:
Table 1

IC50 values for various adenosine uptake inhibitors in erythrocytes from human, mouse, rabbit, and hamster

Inhibition of Adenosine Uptake (ex Vivo).

We measured adenosine uptake in blood samples obtained from mice after the oral administration of KF24345, and the effect of KF24345 was compared with those of other adenosine uptake inhibitors.

As shown in Fig. 3, orally administered KF24345 inhibited adenosine uptake into whole blood in a dose-dependent manner. KF24345 at 10 mg/kg produced almost full inhibition of adenosine uptake from 2 to 10 h after the oral administration. Dipyridamole and R75231 also inhibited adenosine uptake; however, inhibition by these drugs disappeared at 8 or 10 h after the oral administration. In addition, higher doses of dipyridamole and R75231were needed for the inhibition equivalent to that by 10 mg/kg KF24345. Orally administered dilazep did not inhibit adenosine uptake at up to 300 mg/kg, although it was more potent than KF24345 in vitro. From these results, we selected a dose of 10 mg/kg in the following studies to investigate anti-inflammatory effects of KF24345 in mice.

Figure 3
View larger version:
Figure 3

Time course of adenosine uptake inhibition in sampled blood cells after oral administration of KF24345 (A), dilazep (B), dipyridamole (C), and R75231 (D) in mice. Blood was sampled at various time intervals and incubated with 1 μM [3H]adenosine for 10 s. Adenosine uptake inhibition was expressed as percentage of inhibition compared with the vehicle-treated group, and values represent means ± S.E. of five animals. ∗,P < 0.05, ∗∗, P < 0.01, and ∗∗∗, P < 0.001, differ significantly from the vehicle-treated group.

Effects of KF24345 on LPS-Induced TNF-α Production in Mice.

KF24345 (10 mg/kg p.o.) significantly suppressed the elevation of serum TNF-α concentrations in the control mice treated with LPS (Fig.4A). ZM 241385 (3 mg/kg i.v.), but not KW-3902 (0.3 mg/kg i.v.), completely reversed the suppressing effect of KF24345 (Fig. 4A). Neither KW-3902 nor ZM 241385 alone affected LPS-induced TNF-α production (Fig. 4B).

Figure 4
View larger version:
Figure 4

A, suppression by KF24345 of LPS-induced TNF-α production and the effects of selective adenosine receptor antagonists on the suppression by KF24345. B, effects of selective adenosine receptor antagonists on LPS-induced TNF-α production. Mice were pretreated with KF24345 (10 mg/kg p.o.) 1 h before intravenous injection of LPS (1 mg/kg). KW-3902 (a selective adenosine A1 receptor antagonist; 0.3 mg/kg) or ZM 241385 (a selective adenosine A2 receptor antagonist; 3 mg/kg) was intravenously administered 10 min before the LPS injection. Blood samples were collected 1 h after the LPS injection, and serum TNF-α concentrations were measured by enzyme-linked immunosorbent assay. Values are means ± S.E. of six animals. ∗∗,P < 0.01 and ∗∗∗, P < 0.001 differ significantly from the LPS-treated group; †††,P < 0.001, significantly different from the KF24345 + LPS-treated group.

Effects of KF24345 on LPS-Induced Leukopenia in Mice.

LPS caused a significant reduction in leukocyte counts, and pretreatment with KF24345 (10 mg/kg p.o.) significantly inhibited the drop in leukocyte counts (Fig. 5A). 8-SPT (20 mg/kg i.v.) almost completely reversed the inhibitory effect of KF24345 on LPS-induced leukopenia (Fig. 5A). 8-SPT alone did not affect LPS-induced leukopenia (Fig. 5B).

Figure 5
View larger version:
Figure 5

A, inhibition by KF24345 of LPS-induced leukopenia and the effect of 8-SPT (a nonselective adenosine receptor antagonist) on the inhibition by KF24345. B, effect of 8-SPT on LPS-induced leukopenia. Mice were pretreated with KF24345 (10 mg/kg p.o.) 1 h before intravenous injection of LPS (3 μg/kg). 8-SPT (20 mg/kg) was intravenously administered 10 min before the LPS injection. Blood samples were collected 2 h after the LPS injection, and total leukocyte counts were obtained. Values are means ± S.E. of 5 to 10 animals. ∗, P < 0.05, significantly different from the LPS-treated group; †, P < 0.05, significantly different from the KF24345 + LPS-treated group.

Previous SectionNext Section

Discussion

In this study, we demonstrated that a newly synthesized KF24345 is an orally effective and long-lasting adenosine uptake inhibitor in mice. We also found that KF24345 suppressed LPS-induced TNF-α production and leukopenia in mice. The suppressing effects of KF24345 were completely reversed by adenosine receptor antagonists, suggesting that the effects of KF24345 were mediated by endogenous adenosine and adenosine receptors. These are the first demonstrations that an adenosine uptake inhibitor exhibits anti-inflammatory effects via endogenous adenosine in vivo.

We first studied the in vitro activity of KF24345 as an adenosine uptake inhibitor. KF24345 inhibited adenosine uptake into washed erythrocytes in concentration-dependent manners in all the species examined. KF24345 was slightly less potent than dilazep, but essentially as potent as R75231. The IC50 values of dilazep in this study were similar to those previously reported (Baer et al., 1990). In the ex vivo studies in mice, examining the adenosine uptake into sampled blood cells, KF24345 was the most potent inhibitor with long duration of action among all the inhibitors tested, although its in vitro potency was not remarkably different from those of other inhibitors. Plasma concentrations of KF24345 2 h after its oral administration at 1, 3, and 10 mg/kg were 77, 292, and 1277 nM, respectively (H. Ohtsuka, unpublished observation). The plasma concentrations of KF24345 were 383 and 252 nM, respectively, at 8 and 12 h after the oral administration at a dose of 10 mg/kg. In another experiment, in vitro inhibitory activities of adenosine uptake by KF24345 at various concentrations scarcely changed even after the washout of the drug with saline (unpublished observation). Thus, it is considered that the strong binding of KF24345 to nucleoside transporters on erythrocytes as well as the long-lasting plasma level contributed to its long duration of action in vivo. The present results suggest that KF24345 is a useful drug for examining the in vivo effects of adenosine uptake inhibition in mice.

At inflamed sites, production and release of adenosine are increased due to enhanced cellular ATP catabolism in response to oxidants and other toxins. In addition, neutrophils are shown to release adenosine at inflamed sites (Newby et al., 1983). A previous report demonstrates that not only exogenous but also endogenous adenosine attenuates TNF-α production from human mononuclear cells in vitro (Eigler et al., 1997). However, the effects of extracellular adenosine are extremely short-lived because it is rapidly taken up from the extracellular fluid into cells and metabolized (Dawicki et al., 1985;Moser et al., 1989). In contrast, if the adenosine uptake inhibitor could continuously increase endogenous adenosine at inflamed sites, it would be able to retard the inflammatory response. In this study, indeed, KF24345 reduced TNF-α production and diminished leukocyte accumulation, which supposedly result from leukocyte accumulation at inflamed sites, suggesting an anti-inflammatory property of this drug. One possible mechanism by which KF24345 diminished leukopenia is considered to be inhibited expression of adhesion molecules in the stimulated vascular endothelium and/or neutrophils. Indeed, adenosine has been reported to inhibit expression of E-selectin and vascular cell adhesion molecule 1 in the activated vascular endothelial cells (Bouma et al., 1996). These are the first demonstrations that the adenosine uptake inhibitor is anti-inflammatory in vivo.

Adenosine has been described to inhibit various functions of inflammatory cells through activation of adenosine receptors on the cell surface. Adenosine suppresses neutrophil functions, such as oxygen radical production, adhesion to vascular endothelium and phagocytosis, and macrophage functions, including TNF-α production, in vitro (Cronstein et al., 1985; Salmon and Cronstein, 1990; Cronstein et al., 1992; Parmely et al., 1993; Bouma et al., 1994). Furthermore, previous reports have shown that adenosine and its agonists exert anti-inflammatory effects in vivo (Schrier et al., 1990; Le Vraux et al., 1993). In the present study, the inhibition by KF24345 of LPS-induced leukopenia was completely reversed by 8-SPT, a nonselective adenosine receptor antagonist. In addition, the suppression of LPS-induced TNF-α production by KF24345 was completely blocked by ZM 241385, a selective adenosine A2 receptor antagonist. Moreover, the suppressing effect of KF24345 on LPS-induced TNF-α production was also reversed by 8-SPT (unpublished observation). These results suggest that the anti-inflammatory effect of KF24345 is mediated by endogenous adenosine and adenosine receptor pathway, especially adenosine A2receptor stimulation.

Although the anti-inflammatory effects of KF24345 were blocked by adenosine receptor antagonists, systemic blood pressure in mice was shown to be unaffected from 1 to 8 h after the oral administration in mice (K. Yao, unpublished observation), suggesting that systemic adenosine levels were unchanged during this period. Thus, we could expect that KF24345 would diminish inflammation with minimal systemic side effects, as was previously reported in an animal model of cardiac infarction (Belardinelli et al., 1989). On the other hand, adenosine kinase inhibitors are reported to exhibit anti-epileptic, neuroprotective, and analgesic effects as well as anti-inflammatory effect (Kowaluk et al., 1998). Thus, when used as an anti-inflammatory drug, adenosine kinase inhibitors may elicit side effects, especially those in the central nervous system, after systemic administration. Collectively, KF24345 may be a potent and new anti-inflammatory agent with minimal systemic side effects and also may render effective therapies for some inflammatory diseases.

In conclusion, we have shown that KF24345, an orally effective adenosine uptake inhibitor, suppresses LPS-induced TNF-α production and leukopenia in mice. Endogenously increased adenosine, which inhibits leukocyte accumulation and suppresses cytokine production, could contribute to the anti-inflammatory effects of KF24345 at inflamed sites. These data suggest that adenosine uptake inhibitors could be effective in the treatment or prevention of various inflammatory diseases.

Previous SectionNext Section

Acknowledgments

We thank Mika Kawai and Maya Nagai for excellent technical assistance. We are also grateful to Drs. Fumio Suzuki, Yoshikazu Morishita, and Setsuya Sasho for encouragement and support.

Previous SectionNext Section

Footnotes

  • Abbreviations:
    KF24345
    3-[1-(6,7-diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6-dimethyl-2,4(1H,3H)-quinazolinedione hydrochloride
    LPS
    lipopolysaccharide
    TNF-α
    tumor necrosis factor-α
    ZM 241385
    4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol
    8-SPT
    8-(p-sulfophenyl)theophylline
    R75231
    2-(aminocarbonyl)-N-(4-amino-2,6-dichlorophenyl)-4-[5,5-bis(4-fluorophenyl)pentyl]-1-piperazineacetamide
    KW-3902
    8-(noradamantan-3-yl)-1,3-dipropylxanthine
    • Received May 30, 2001.
    • Accepted September 21, 2001.
Previous Section
 

References

  1. ↵
    1. Arch JR,
    2. Newsholme EA
    (1978) The control of the metabolism and the hormonal role of adenosine. Essays Biochem 14:82–123.
    Medline
  2. ↵
    1. Baer HP,
    2. Haq A,
    3. El-Soofi A,
    4. Serignese V,
    5. Paterson ARP
    (1990) Potencies of mioflazine and its derivatives as inhibitors of adenosine transport in isolated erythrocytes from different species. J Pharm Pharmacol 42:367–369.
    Medline
  3. ↵
    1. Baer HP,
    2. Serignese V,
    3. Moorji A,
    4. Van Belle H
    (1991) In vivo effectiveness of several nucleoside transport inhibitors in mice and hamsters. Naunyn-Schmiedeberg's Arch Pharmacol 343:365–369.
    Medline
  4. ↵
    1. Belardinelli L,
    2. Linden J,
    3. Berne RM
    (1989) The cardiac effects of adenosine. Prog Cardiovasc Dis 32:73–97.
    CrossRefMedlineWeb of Science
  5. ↵
    1. Beukers MW,
    2. Kerkhof CJM,
    3. IJzerman AP,
    4. Soudijn W
    (1994) Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016. Eur J Pharmacol 266:57–62.
    CrossRefMedline
  6. ↵
    1. Bouma MG,
    2. Stad RK,
    3. van den Wildenberg FA,
    4. Buurman WA
    (1994) Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153:4159–4168.
    Abstract
  7. ↵
    1. Bouma MG,
    2. van den Wildenberg FA,
    3. Buurman WA
    (1996) Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 270:C522–C529.
    Abstract/FREE Full Text
  8. ↵
    1. Collis MG,
    2. Hourani SMO
    (1993) Adenosine receptor subtypes. Trends Pharmacol Sci 14:360–366.
    Medline
  9. ↵
    1. Cronstein BN
    (1995) A novel approach to the development of anti-inflammatory agents: adenosine release at inflamed sites. J Invest Med 43:50–57.
    MedlineWeb of Science
  10. ↵
    1. Jacobson KA,
    2. Jarvis MF
    1. Cronstein BN
    (1997) Adenosine regulation of neutrophil function and inhibition of inflammation via adenosine receptors. in Purinergic Approaches in Experimental Therapeutics, eds Jacobson KA, Jarvis MF (Wiley-Liss, Inc. New York), pp 285–299.
  11. ↵
    1. Cronstein BN,
    2. Levin RI,
    3. Philips M,
    4. Hirschhorn R,
    5. Abramson SB,
    6. Weissmann G
    (1992) Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 148:2201–2206.
    Abstract
  12. ↵
    1. Cronstein BN,
    2. Naime D,
    3. Firestein G
    (1995) The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 38:1040–1045.
    MedlineWeb of Science
  13. ↵
    1. Cronstein BN,
    2. Rosenstein ED,
    3. Kramer SB,
    4. Weissmann G,
    5. Hirschhorn R
    (1985) Adenosine: a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J Immunol 135:1366–1371.
    Abstract
  14. ↵
    1. Dawicki DD,
    2. Agarwal KC,
    3. Parks RE, Jr
    (1985) Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol 34:3965–3972.
    CrossRefMedline
  15. ↵
    1. Dunwiddie TV,
    2. Worth T
    (1982) Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J Pharmacol Exp Ther 220:70–76.
    Abstract/FREE Full Text
  16. ↵
    1. Eigler A,
    2. Greten TF,
    3. Sinha B,
    4. Haslberger C,
    5. Sullivan GW,
    6. Endres S
    (1997) Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand J Immunol 45:132–139.
    CrossRefMedlineWeb of Science
  17. ↵
    1. Firestein GS,
    2. Boyle D,
    3. Bullough DA,
    4. Gruber HE,
    5. Sajjadi FG,
    6. Montag A,
    7. Sambol B,
    8. Mullane KM
    (1994) Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 152:5853–5859.
    Abstract
  18. ↵
    1. Fredholm BB,
    2. Burnstock G,
    3. Abbracchio MP,
    4. Daly JW,
    5. Hardin TK,
    6. Jacobson KA,
    7. Williams M
    (1994) Nomenclature and classification of purinoceptors: a report from the IUPHAR Subcommittee. Pharmacol Rev 46:143–156.
    MedlineWeb of Science
  19. ↵
    1. Jarvis SM,
    2. Young JD
    (1986) Nucleoside transport in rat erythrocytes: two components with differences in sensitivity to inhibition by nitrobenzylthioinosine and p-chloromercuriphenyl sulfonate. J Membr Biol 93:1–10.
    CrossRefMedline
  20. ↵
    1. Johnson SM,
    2. Patel S,
    3. Bruckner FE,
    4. Collins DA
    (1999) 5′-Nucleotidase as a marker of both general and local inflammation in rheumatoid arthritis patients. Rheumatology 38:391–396.
    Abstract/FREE Full Text
  21. ↵
    1. Keddie JR,
    2. Poucher SM,
    3. Shaw GR,
    4. Brooks R,
    5. Collis MG
    (1996) In vivo characterisation of ZM 241385, a selective adenosine A2A receptor antagonist. Eur J Pharmacol 301:107–113.
    CrossRefMedlineWeb of Science
  22. ↵
    1. Kowaluk EA,
    2. Bhagwat SS,
    3. Jarvis MF
    (1998) Adenosine kinase inhibitors. Curr Pharm Design 4:403–416.
    Medline
  23. ↵
    1. Kowaluk EA,
    2. Mikusa J,
    3. Wismer CT,
    4. Zhu CZ,
    5. Schweitzer E,
    6. Lynch JJ,
    7. Lee CH,
    8. Jiang M,
    9. Bhagwat SS,
    10. Gomtsyan A,
    11. et al.
    (2000) ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d] pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. J Pharmacol Exp Ther 295:1165–1174.
    Abstract/FREE Full Text
  24. ↵
    1. Le Vraux V,
    2. Chen YL,
    3. Masson I,
    4. De Sousa M,
    5. Giroud JP,
    6. Florentin I,
    7. Chauvelot-Moachon L
    (1993) Inhibition of human monocyte TNF production by adenosine receptor agonists. Life Sci 52:1917–1924.
    CrossRefMedlineWeb of Science
  25. ↵
    1. Mizumoto H,
    2. Karasawa A,
    3. Kubo K
    (1993) Diuretic and renal protective effects of 8-(noradamantan-3-yl)-1,3-dipropylxanthine (KW-3902), a novel adenosine A1-receptor antagonist, via pertussis toxin insensitive mechanism. J Pharmacol Exp Ther 266:200–206.
    Abstract/FREE Full Text
  26. ↵
    1. Moser GH,
    2. Schrader J,
    3. Deussen A
    (1989) Turnover of adenosine in plasma of human and dog blood. Am J Physiol 256:C799–C806.
    Abstract/FREE Full Text
  27. ↵
    1. Murray TF,
    2. Sylvester D,
    3. Schultz CS,
    4. Szot P
    (1985) Purinergic modulation of the seizure threshold for pentylenetetrazol in the rat. Neuropharmacology 24:761–766.
    CrossRefMedline
  28. ↵
    1. Newby AC,
    2. Holmquist CA,
    3. Illingworth J,
    4. Pearson JD
    (1983) The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. Biochem J 214:317–323.
    Medline
  29. ↵
    1. Olah ME,
    2. Stiles GL
    (1995) Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35:581–606.
    CrossRefMedlineWeb of Science
  30. ↵
    1. Parmely MJ,
    2. Zhou WW,
    3. Edwards CK, 3d,
    4. Borcherding DR,
    5. Silverstein R,
    6. Morrison DC
    (1993) Adenosine and related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J Immunol 151:389–396.
    Abstract
  31. ↵
    1. Poucher SM,
    2. Keddie JR,
    3. Brooks R,
    4. Shaw GR,
    5. Mckillop D
    (1996) Pharmacodynamics of ZM 241385, a potent A2a adenosine receptor antagonist, after enteric administration in rat, cat and dog. J Pharm Pharmacol 48:601–606.
    MedlineWeb of Science
  32. ↵
    1. Ralevic V,
    2. Burnstock G
    (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413–492.
    Abstract/FREE Full Text
  33. ↵
    1. Jacobson KA,
    2. Jarvis MF
    1. Rosengren S,
    2. Firestein GS
    (1997) Purinergic modulation of septic shock and systemic inflammation response syndrome. in Purinergic Approaches in Experimental Therapeutics, eds Jacobson KA, Jarvis MF (Wiley-Liss, Inc. New York), pp 301–313.
  34. ↵
    1. Salmon JE,
    2. Cronstein BN
    (1990) Fcgamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy: A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol 145:2235–2240.
    Abstract
  35. ↵
    1. Sawynok J,
    2. Sweeney MI,
    3. White TD
    (1986) Classification of adenosine receptors mediating antinociception in the rat spinal cord. Br J Pharmacol 88:923–930.
    MedlineWeb of Science
  36. ↵
    1. Schrier DJ,
    2. Lesch ME,
    3. Wright CD,
    4. Gilbertsen RB
    (1990) The antiinflammatory effects of adenosine receptor agonists on the carrageenan-induced pleural inflammatory response in rats. J Immunol 145:1874–1879.
    Abstract
  37. ↵
    1. Shimada J,
    2. Suzuki F,
    3. Nonaka H,
    4. Ishii A
    (1992) 8-polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors. J Med Chem 35:924–930.
    CrossRefMedline
  38. ↵
    1. Toombs CF,
    2. McGee DS,
    3. Johnston WE,
    4. Vinten-Johansen J
    (1992) Myocardial protective effects of adenosine: infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation 86:986–994.
    Abstract/FREE Full Text
  39. ↵
    1. von Lubitz DK,
    2. Dambrosia JM,
    3. Kempski O,
    4. Redmond DJ
    (1988) Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of gerbil hippocampus. Stroke 19:1133–1139.
    Abstract/FREE Full Text
  40. ↵
    1. Williams M
    (1996) Progress towards purinoceptor based therapeutics. Curr Opin Invest Drugs 2:1105–1117.
« Previous | Next Article »Table of Contents

This Article

  1. doi: 10.1124/jpet.300.1.200 JPET January 1, 2002 vol. 300 no. 1 200-205
  1. AbstractFree
  2. » Full Text
  3. Full Text (PDF)

Responses

  1. Submit a response
  2. No responses published

Navigate This Article

Current Issue

  1. November 2009, 331 (2)
  1. Current Issue
  1. Alert me to new issues of JPET